Overview

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Status:
Terminated

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.

Phase:

Phase 4

Details

Lead Sponsor:

Baxter Healthcare Corporation

Collaborator:

Halozyme Therapeutics

Treatments:

Pharmaceutical Solutions